News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
39,188 Results
Type
Article (2493)
Company Profile (39)
Press Release (36652)
Multimedia
Podcasts (6)
Webinars (2)
Section
Business (14200)
Career Advice (78)
Deals (2097)
Drug Delivery (9)
Drug Development (4121)
Employer Resources (10)
FDA (438)
Job Trends (771)
News (20245)
Policy (1053)
Tag
Academia (144)
Allergies (7)
Alliances (3492)
ALS (4)
Alzheimer's disease (51)
Antibody-drug conjugate (ADC) (20)
Approvals (437)
Artificial intelligence (18)
Autoimmune disease (3)
Automation (1)
Bankruptcy (12)
Best Places to Work (475)
BIOSECURE Act (2)
Biosimilars (13)
Biotechnology (29)
Bladder cancer (7)
Brain cancer (6)
Breast cancer (28)
Cancer (218)
Cardiovascular disease (5)
Career advice (64)
Career pathing (1)
CAR-T (22)
Cell therapy (61)
Cervical cancer (2)
Clinical research (3279)
Collaboration (136)
Company closure (2)
Compensation (73)
COVID-19 (181)
CRISPR (9)
C-suite (51)
Cystic fibrosis (5)
Data (215)
Denatured (5)
Depression (8)
Diabetes (14)
Diagnostics (472)
Digital health (1)
Diversity (1)
Diversity, equity & inclusion (1)
Drug discovery (18)
Drug pricing (8)
Duchenne muscular dystrophy (22)
Earnings (4435)
Editorial (3)
Employer branding (1)
Employer resources (8)
Events (6225)
Executive appointments (119)
FDA (526)
Funding (105)
Gene editing (20)
Gene therapy (29)
GLP-1 (61)
Government (151)
Guidances (21)
Healthcare (709)
Huntington's disease (4)
IgA nephropathy (8)
Immunology and inflammation (25)
Immuno-oncology (4)
Indications (3)
Infectious disease (189)
Inflammatory bowel disease (13)
Inflation Reduction Act (6)
Influenza (7)
Intellectual property (15)
Interviews (7)
IPO (1007)
IRA (7)
Job creations (290)
Job search strategy (62)
Kidney cancer (6)
Labor market (8)
Layoffs (44)
Leadership (1)
Legal (213)
Liver cancer (6)
Longevity (1)
Lung cancer (20)
Lymphoma (8)
Management (4)
Manufacturing (28)
MASH (6)
Medical device (311)
Medtech (311)
Mergers & acquisitions (1184)
Metabolic disorders (43)
Multiple sclerosis (14)
Neurodegenerative disease (19)
Neuropsychiatric disorders (5)
Neuroscience (123)
NextGen: Class of 2025 (352)
Non-profit (154)
Now hiring (7)
Obesity (19)
Opinion (15)
Ovarian cancer (15)
Pain (14)
Pancreatic cancer (13)
Parkinson's disease (7)
Partnered (2)
Patents (37)
Patient recruitment (10)
Peanut (1)
People (5753)
Pharmaceutical (5)
Phase I (1409)
Phase II (1633)
Phase III (876)
Pipeline (177)
Policy (14)
Postmarket research (30)
Preclinical (617)
Press Release (2)
Prostate cancer (5)
Psychedelics (2)
Radiopharmaceuticals (13)
Rare diseases (37)
Real estate (422)
Recruiting (5)
Regulatory (839)
Reports (7)
Research institute (143)
Resumes & cover letters (9)
RNA editing (5)
Schizophrenia (15)
Series A (30)
Series B (11)
Service/supplier (2)
Sickle cell disease (2)
Special edition (3)
Spinal muscular atrophy (2)
Sponsored (1)
Startups (495)
Stomach cancer (2)
Supply chain (4)
The Weekly (1)
Vaccines (39)
Venture capital (10)
Weight loss (13)
Women's health (3)
Worklife (1)
Date
Today (5)
Last 7 days (31)
Last 30 days (189)
Last 365 days (2472)
2025 (1638)
2024 (2627)
2023 (2886)
2022 (3783)
2021 (4076)
2020 (3473)
2019 (2061)
2018 (1554)
2017 (1796)
2016 (1625)
2015 (1833)
2014 (1369)
2013 (1188)
2012 (1396)
2011 (1332)
2010 (1181)
Location
Africa (44)
Alabama (2)
Arizona (16)
Asia (1901)
Australia (302)
California (1206)
Canada (188)
China (52)
Colorado (48)
Connecticut (12)
Delaware (4)
Europe (3906)
Florida (52)
Georgia (11)
Hawaii (2)
Idaho (3)
Illinois (17)
India (1)
Indiana (39)
Japan (12)
Kansas (12)
Kentucky (1)
Maryland (33)
Massachusetts (423)
Michigan (11)
Minnesota (18)
Mississippi (1)
Missouri (4)
Nebraska (1)
Nevada (3)
New Hampshire (2)
New Jersey (96)
New York (61)
North Carolina (107)
Northern California (543)
Ohio (31)
Oklahoma (2)
Oregon (5)
Pennsylvania (77)
Rhode Island (2)
South America (40)
South Carolina (1)
Southern California (499)
Tennessee (3)
Texas (110)
United States (2431)
Utah (3)
Virginia (7)
Washington D.C. (1)
Washington State (70)
West Virginia (1)
Wisconsin (7)
39,188 Results for "aytu bioscience".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Aytu BioPharma Appoints Dr. Gerwin Westfield as Senior Vice President of Scientific Affairs to Support Commercialization of EXXUA(TM)
June 25, 2025
·
7 min read
Press Releases
Aytu BioPharma Announces At the Market Pricing of $14.4 Million Upsized Public Offering of Common Stock
June 9, 2025
·
4 min read
Press Releases
Aytu BioPharma Expands and Extends Lending Agreement with Eclipse Following Agreement to Commercialize First-in-Class Antidepressant EXXUA(TM)
June 23, 2025
·
6 min read
Press Releases
Aytu BioPharma Reports Fiscal 2025 Third Quarter Operational and Financial Results
May 14, 2025
·
14 min read
Press Releases
Aytu BioPharma to Report Fiscal 2025 Third Quarter Operational and Financial Results on May 14, 2025
May 8, 2025
·
1 min read
Press Releases
Aytu BioPharma to Present at the Planet MicroCap Showcase: VEGAS 2025 on April 23, 2025
April 21, 2025
·
1 min read
Press Releases
Aytu BioPharma Announces Exclusive Agreement with Fabre-Kramer Pharmaceuticals to Commercialize First-in-Class Antidepressant EXXUA(TM) (gepirone) Extended-Release Tablets in the United States
June 9, 2025
·
9 min read
Press Releases
Aytu BioPharma Announces Closing of Upsized At the Market Public Offering of Common Stock with Full Exercise of Overallotment and Conference Call to Discuss First-in-Class Antidepressant EXXUA(TM) Opportunity and Commercialization Plan
June 10, 2025
·
7 min read
Aytu BioPharma Announces Paydown and Refinancing of Term Loan on More Favorable Terms
Aytu BioPharma, Inc. today announced the successful refinancing of its existing term loan and extension of its revolving credit facility on more favorable terms to the Company.
June 18, 2024
·
6 min read
Business
Aytu BioPharma to Report Third Quarter Fiscal 2024 Financial and Operational Results on May 15, 2024
Aytu BioPharma, Inc. (the “Company” or “Aytu”) (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report its financial and operational results for its third quarter of fiscal 2024 for the period ended March 31, 2024, after the market close on Wednesday, May 15, 2024.
May 8, 2024
·
1 min read
1 of 3,919
Next
